|Bid||117.22 x 1100|
|Ask||117.23 x 900|
|Day's range||116.01 - 122.33|
|52-week range||66.89 - 144.96|
|Beta (5Y monthly)||1.13|
|PE ratio (TTM)||261.06|
|Earnings date||08 Feb 2023 - 13 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||125.24|
With the Nasdaq Composite still firmly entrenched in bear market territory, if you're feeling discouraged about the state of your portfolio and the performance of some of your favorite stocks, you're certainly not alone. Two stocks that in my view belong firmly in the former category are DexCom (NASDAQ: DXCM) and Procter & Gamble (NYSE: PG). If you're searching for a non-cyclical company with products that are consistently in demand, regardless of the macro environment or consumer sentiment, DexCom could be a no-brainer contender for your portfolio.
SAN DIEGO, December 08, 2022--Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.
With that, let's take a look at two top growth stocks to consider adding to your portfolio before the year is out. On the contrary, Etsy stands to benefit considerably from the consumer-driven tailwinds driving prolonged growth in the global e-commerce market, a space on track to hit a valuation of roughly $63 trillion by the year 2030.